Literature DB >> 16147992

Analysis of BCL6-interacting proteins by tandem mass spectrometry.

Rodney R Miles1, David K Crockett, Megan S Lim, Kojo S J Elenitoba-Johnson.   

Abstract

B-cell lymphoma 6 (BCL6) is a 95-kDa nuclear phosphoprotein and member of the Pox virus zinc finger/bric-a-brac, tramtrack, broad complex (POZ/BTB) family of transcription factors. BCL6 is a transcriptional repressor required for germinal center formation, and the gene encoding it is frequently altered in diffuse large B-cell and follicular lymphomas. The dysregulation of BCL6 has therefore been implicated in lymphomagenesis. A limited number of proteins is known to interact with BCL6 and modulate its activity or participate in its role in transcriptional regulation. Identification of additional BCL6-binding proteins could reveal potential signaling targets and previously undescribed functional roles for BCL6. We used a functional proteomic approach to determine the identity of proteins that interact with BCL6. Proteins were isolated by co-immunoprecipitation with an anti-BCL6 antibody and identified using MS/MS. We identified 61 proteins in the BCL6 immunocomplex from the following Gene Ontology categories: transcription regulator activity (n = 18), binding activity (n = 11), signal transducer activity (n = 10), catalytic activity (n = 8), structural molecule activity (n = 3), enzyme regulator activity (n = 3), transporter activity (n = 2), motor activity (n = 2), chaperone activity (n = 1), and unknown function (n = 3). Importantly we identified BCL6 and several previously reported BCL6-interacting proteins in the BCL6 immunocomplex. The remaining proteins have not been shown previously to be associated with BCL6. MS/MS results were validated on four proteins using immunoprecipitation and Western blotting. Two of these protein interactions were further confirmed by reciprocal immunoprecipitation. This study demonstrates the utility of antibody immunoprecipitation and subsequent peptide identification by MS/MS for the elucidation of BCL6-binding proteins. Many of the novel proteins identified in this study suggest additional functional roles for BCL6 beyond transcriptional repression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16147992     DOI: 10.1074/mcp.M500112-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  20 in total

Review 1.  Common mechanisms for the regulation of B cell differentiation and transformation by the transcriptional repressor protein BCL-6.

Authors:  Saritha Kusam; Alexander Dent
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 3.  BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint.

Authors:  Srividya Swaminathan; Cihangir Duy; Markus Müschen
Journal:  Trends Immunol       Date:  2013-12-10       Impact factor: 16.687

4.  miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.

Authors:  Sukhinder K Sandhu; Stefano Volinia; Stefan Costinean; Marco Galasso; Reid Neinast; Ramasamy Santhanam; Mark R Parthun; Danilo Perrotti; Guido Marcucci; Ramiro Garzon; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

Review 5.  Structure and function insights into the NuRD chromatin remodeling complex.

Authors:  Morgan P Torchy; Ali Hamiche; Bruno P Klaholz
Journal:  Cell Mol Life Sci       Date:  2015-03-22       Impact factor: 9.261

6.  TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.

Authors:  Leandro Venturutti; Matt Teater; Andrew Zhai; Amy Chadburn; Leena Babiker; Daleum Kim; Wendy Béguelin; Tak C Lee; Youngjun Kim; Christopher R Chin; William T Yewdell; Brian Raught; Jude M Phillip; Yanwen Jiang; Louis M Staudt; Michael R Green; Jayanta Chaudhuri; Olivier Elemento; Pedro Farinha; Andrew P Weng; Michael D Nissen; Christian Steidl; Ryan D Morin; David W Scott; Gilbert G Privé; Ari M Melnick
Journal:  Cell       Date:  2020-07-02       Impact factor: 41.582

Review 7.  Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Authors:  Samir Parekh; Gilbert Privé; Ari Melnick
Journal:  Leuk Lymphoma       Date:  2008-05

8.  Depletion of histone demethylase KDM2A inhibited cell proliferation of stem cells from apical papilla by de-repression of p15INK4B and p27Kip1.

Authors:  Runtao Gao; Rui Dong; Juan Du; Ping Ma; Songlin Wang; Zhipeng Fan
Journal:  Mol Cell Biochem       Date:  2013-04-05       Impact factor: 3.396

9.  BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

Authors:  Samir Parekh; Jose M Polo; Rita Shaknovich; Przemyslaw Juszczynski; Paola Lev; Stella M Ranuncolo; Yingnan Yin; Ulf Klein; Giorgio Cattoretti; Riccardo Dalla Favera; Margaret A Shipp; Ari Melnick
Journal:  Blood       Date:  2007-06-01       Impact factor: 22.113

10.  The Potential Applications of Peroxisome Proliferator-Activated Receptor delta Ligands in Assisted Reproductive Technology.

Authors:  Jaou-Chen Huang
Journal:  PPAR Res       Date:  2008-12-16       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.